ABSK 121
Alternative Names: ABSK-121; ABSK121-NXLatest Information Update: 05 Jul 2023
At a glance
- Originator Abbisko Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Fibroblast growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 26 Jun 2023 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Monotherapy) in China (PO) (NCT05627063) (Abbisko Therapeutics pipeline, September 2023)
- 14 Apr 2023 Pharmacodynamics data from preclinical trials in Solid tumours presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
- 22 Feb 2023 NMPA approves IND application for ABSK 121 in Solid tumours